Bioxytran Inc

OTC: BIXT    
Share price (5/1/24): $0.10    
Market cap (5/1/24): $18.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.83
from 10-Q 4 pages Bioxytran, Inc Stock Option
12/34/56
EX-10.82
from 10-K 4 pages Security Purchase Agreement
12/34/56
EX-10.81
from 10-K 6 pages Bioxytran, Inc. Convertible Note
12/34/56
EX-10.80
from 10-Q 6 pages Common Stock Purchase Option Pharmalectin, Inc
12/34/56
EX-10.79
from S-1 4 pages Closing Agreement
12/34/56
EX-10.78
from S-1 6 pages Debt Modification Agreement
12/34/56
EX-10.77
from S-1/A 4 pages Amended Closing Agreement
12/34/56
EX-10.76
from 8-K 5 pages Closing Agreement
12/34/56
EX-10.75
from 8-K 1 page Amendment to Engagement Letter
12/34/56
EX-10.74
from 10-Q 10 pages The Offering
12/34/56
EX-10.73
from 10-Q 40 pages Confidential Private Placement Memorandum Bioxytran, Inc. Price to Subscribers Commissions (1) Fees (2) Proceeds to Company Maximum Offering $ 3,000,000 — — $ 3,000,000
12/34/56
EX-10.56
from 8-K ~5 pages Amendment to Employment Agreement
12/34/56
EX-10.72
from 8-K 9 pages The Offering
12/34/56
EX-10.71
from 8-K 1 page Official Uspto Notice of Publication Under 12(a) U.S. Application Serial No. 90888912 Mark: Prolectin International Class(es): 005 Owner: Pharmalectin, Inc. Docket/Reference No. 51577-T02001 Issue Date: June 8, 2022 Your Mark Is Scheduled to Publish in the Trademark Official Gazette (Tmog) on June 28, 2022
12/34/56
EX-10.70
from 8-K 1 page Approval of International Patent Wo2022/099061 - Polysaccharides for IV Administration That Treat Sars-Cov-2 Infections, Dated May 12, 2022
12/34/56
EX-10.69
from 8-K 1 page Approval of International Patent Wo2022/099052 - Polysaccharides for Use in Treating Sars-Cov-2 Infections, Dated May 12, 2022
12/34/56
EX-10.68
from 8-K 7 pages Note Purchase Agreement
12/34/56
EX-10.67
from 8-K 12 pages Bioxytran, Inc. Convertible Note
12/34/56
EX-10.66
from 10-Q 39 pages Confidential Private Placement Memorandum Bioxytran, Inc. Price to Subscribers Commissions(1) Fees (2) Proceeds to Company Maximum Offering $1,000,000 $90,000 $20,000 $890,000
12/34/56
EX-10.65
from 10-Q 41 pages Confidential Private Placement Memorandum Bioxytran, Inc. Price to Subscribers Commissions(1) Fees (2) Proceeds to Company Maximum Offering $1,200,000 $132,000 $20,000 $1,048,000
12/34/56